Shots:Sangamo regains rights to giroctocogene fitelparvovec (gene therapy for hemophilia A) as Pfizer ends their collaboration (effective Apr 21, 2025) & decids not to file BLA or MAA to pursue commercialization. Sangamo plans to seek a new partner
The drug is in P-III (AFFINE) trial involving 75 adult males with severe hemophilia A…
